“Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma: Expansion Cohort Analysis”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s179, https://doi.org/10.25251/skin.7.supp.179.